bluuebunny/crossref_metadata_2025_split huggingface dataset:
Self-reported health without clinically measurable benefits among adult users of multivitamin and multimineral supplements: a cross-sectional study
Authors: Paranjpe Manish D , Chin Alfred C , Paranjpe Ishan , Reid Nicholas J , Duy Phan Q , Wang Jason K , O'Hagan Ross , Arzani Artine , Haghdel Arsalan , Lim Clarence C , Orhurhu Vwaire , Urits Ivan , Ngo Anh L , Glicksberg Benjamin S , Hall Kathryn T , Mehta Darshan , Cooper Richard S , Nadkarni Girish N 
Published: November 2020

ObjectiveMultiple clinical trials fail to identify clinically measurable health benefits of daily multivitamin and multimineral (MVM) consumption in the general adult population. Understanding the determinants of widespread use of MVMs may guide efforts to better educate the public about effective nutritional practices. The objective of this study was to compare self-reported and clinically measurable health outcomes among MVM users and non-users in a large, nationally representative adult civilian non-institutionalised population in the USA surveyed on the use of complementary health practices.DesignCross-sectional analysis of the effect of MVM consumption on self-reported overall health and clinically measurable health outcomes.ParticipantsAdult MVM users and non-users from the 2012 National Health Interview Survey (n=21 603).Primary and secondary outcome measuresFive psychological, physical, and functional health outcomes: (1) self-rated health status, (2) needing help with routine needs, (3) history of 10 chronic diseases, (4) presence of 19 health conditions in the past 12 months, and (5) Kessler 6-Item (K6) Psychological Distress Scale to measure non-specific psychological distress in the past month.ResultsAmong 4933 adult MVM users and 16 670 adult non-users, MVM users self-reported 30% better overall health than non-users (adjusted OR 1.31; 95% CI 1.17 to 1.46; false discovery rate adjusted p<0.001). There were no differences between MVM users and non-users in history of 10 chronic diseases, number of present health conditions, severity of current psychological distress on the K6 Scale and rates of needing help with daily activities. No effect modification was observed after stratification by sex, education, and race.ConclusionsMVM users self-reported better overall health despite no apparent differences in clinically measurable health outcomes. These results suggest that widespread use of multivitamins in adults may be a result of individuals’ positive expectation that multivitamin use leads to better health outcomes or a self-selection bias in which MVM users intrinsically harbour more positive views regarding their health.
Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial
Authors: Zheng Rong , Wang Congfei , Huang Xiaoxue , Lin Qingliang , Huang Daxin , Li Xiao-Bo , Huang Heguang , Xu Benhua 
Published: November 2020

IntroductionThe question of how to administer adequate chemotherapy to synchronise stereotactic body radiation therapy (SBRT) treatment strategy to maximise the benefits of neoadjuvant therapy for the improved prognosis of patients with borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer is a challenging and debatable issue. No studies have yet evaluated the efficacy of split-course SBRT as the neoadjuvant chemoradiotherapy regimen. We aimed to study whether neoadjuvant chemotherapy plus split-course SBRT results in better outcomes in BRPC and LAPC patients.Methods and analysisTreatment-naïve patients with radiographically confirmed BRPC or LAPC, supporting biopsy results and no severe comorbidities will be enrolled. They will be treated with nab-paclitaxel plus gemcitabine (nab-P+Gem) chemotherapy plus split-course SBRT, followed by an investigator’s choice of continuation of treatment with nab-P+Gem or surgery. nab-P+Gem chemotherapy will commence on day 1 for each of six cycles: nab-paclitaxel 125 mg/m2intravenous infusion over approximately 30–45 min, followed by gemcitabine 1000 mg/m2intravenous infusion over about 30 min on days 1 and 15 of each 28-day cycle. During the first and second cycles of chemotherapy, SBRT will be given as a single irradiation of 10 Gy four times (days 2 and 16 of each 28-day cycle). The primary endpoint is progression-free survival; while the secondary outcomes are the time to treatment failure, disease control rate, overall response rate, overall survival, R0 resection rate and incidence of adverse effects.Ethics and disseminationThe study protocol was approved by the Ethics Committee of Xiehe Affiliated Hospital of Fujian Medical University (No. 2019YF015-01). Results from our study will be disseminated in international peer-reviewed journals. All study procedures were developed in order to assure data protection and confidentiality.Trial registration numberNCT04289792.
Quality evaluation of case series describing four-factor prothrombin complex concentrate in oral factor Xa inhibitor-associated bleeding: a systematic review
Authors: Costa Olivia S , Baker William L , Roman-Morillo Yuani , McNeil-Posey Kelly , Lovelace Belinda , White C Michael , Coleman Craig I 
Published: November 2020

IntroductionAs oral factor Xa (oFXa) inhibitor use has increased, so has publication of case series describing related bleeding managed with four-factor prothrombin complex concentrate (4F-PCC).ObjectiveThis review aimed to identify case series describing 4F-PCC management of oFXa inhibitor-related bleeding and appraise their methodological and reporting quality.DesignWe searched Medline and EMBASE (1 January 2011 to 31 May 2020) to identify series of ≥10 patients with oFXa inhibitor-related major bleeding given off-label 4F-PCC. Case series were evaluated using a validated tool adapted for this topic. The tool addressed patient selection, bleed/outcome ascertainment, causal/temporal association and reporting.ResultsWe identified 14 case series. None had ≥100 patients (range=13–84), three were prospective, two detailed appropriate inclusion criteria and four noted consecutive inclusion. While 12 series provided clear/appropriate methods for diagnosis of intracranial haemorrhage (ICH); none did so for extracranial bleeds and it was not clear whether bleeding was adjudicated in any. Haemostatic effectiveness, thrombosis and mortality were together evaluated in 12 series, but only seven used validated methods to evaluate/diagnosis haemostasis in ICH, six in gastrointestinal bleeds, five in other bleeds and three in thrombosis. Independent adjudication of haemostasis (n=1) and thrombosis (n=2) was infrequent. Thirty-day follow-up for mortality and thrombosis was noted in five and seven series. Anticoagulation measurement/levels in at least some patients were conveyed in three series. Few series provided data on anticoagulant agent/dose (n=4), time from anticoagulant (n=4), time-to-reversal (n=7), baseline (n=7) or change (n=0) in neurologic function.ConclusionsAlthough many case series describe off-label use of 4F-PCC for oFXa inhibitor-related bleeding, methodological flaws and/or poor reporting necessitates caution in interpretation.
Identification of factors associated with aggressive end-of-life antitumour treatment: retrospective study of 1282 patients with cancer
Authors: Debourdeau Philippe , Belkacémi Mohamed , Economos Guillaume , Assénat Eric , Hilgers Werner , Coussirou Julie , Kouidri Uzan Sfaya , Vasquez Léa , Debourdeau Antoine , Daures Jean Pierre , Salas Sebastien 
Published: November 2020

ObjectiveAntitumour treatment in the last 2 weeks of death (ATT-W2) and a new regimen of ATT within 30 days of death (NATT-M1) are considered as aggressive end-of-life (EOL) care. We aimed to assess factors associated with inappropriate use of antitumour treatment (ATT) at EOL.MethodsData of patients with cancer who died in 2013, 2015, 2017 and 2019 in a single for-profit cancer centre were retrospectively analysed. ATT was divided into chemotherapy (CT), oral targeted therapy (OTT), hormonotherapy and immunotherapy (IMT).ResultsA total of 1282 patients were included. NATT-M1 was given to 197 (15.37%) patients, and 167 (13.03%) had an ATT-W2. Patients with a performance status of <2 and treated with CT had more both ATT- W2 (OR=2.45, 95% CI 1.65 to 3.65, and OR=10.29, 95% CI 4.70 to 22.6, respectively) and NATT-M1 (OR=2.01, 95% CI 1.40 to 2.90, and OR=8.41, 95% CI 4.46 to 15.86). Predictive factors of a higher rate of ATT-W2 were treatment with OTT (OR=19.08, 95% CI 7.12 to 51.07), follow-up by a medical oncologist (OR=1.49, 95% CI 1.03 to 2.17), miscellaneous cancer (OR=3.50, 95% CI 1.13 to 10.85) and length of hospital stay before death of <13 days (OR=1.92, 95% CI 1.32 to 2.79). Urinary tract and male genital cancers received less ATT-W2 (OR=0.38, 95% CI 0.16 to 0.89, and OR=0.40, 95% CI 0.16 to 0.99) and patients treated by IMT or with age <69 years more NATT-M1 (OR=19.21, 95% CI 7.55 to 48.8, and OR=1.69, 95% CI 1.20 to 2.37). Patients followed up by the palliative care team (PCT) had fewer ATT-W2 and NATT-M1 (OR=0.49, 95% CI 0.35 to 0.71, and OR=0.42, 95% CI 0.30 to 0.58).ConclusionsMost recent ATT and access to a PCT follow-up are the two most important potentially modifiable factors associated with aggressive EOL in patients with cancer. Early integrated palliative oncology care could help to decrease futile ATT at EOL.
Experimental investigation on the installation and loading performance of model-scale deep helical piles in very dense sand
Authors: da Silva Diego Moreira , Tsuha Cristina de Hollanda Cavalcanti 
Published: November 2020

The use of helical piles has grown over the years owing to different advantages, such as large uplift capacity due to the anchor effect of the helix and installation torque-capacity correlation. Although the use of helical foundations is expanding worldwide, some key aspects fundamental to the design are not well understood to date. Practical experience indicates that the installation forces and loading performance of helical piles in sand are dependent on the helices characteristics and confining stresses. Therefore, for a better understanding of these dependencies, the effects of the helix-to-shaft diameter ratio (wing ratio) and vertical confining stress on the installation torque and forces, and on the uplift and compression capacities of helical piles, were evaluated from nine calibration chamber tests, conducted on instrumented single-helix piles in very dense sand. Among other findings, this study indicated that for a certain shaft diameter (i) the wing ratio influences the installation torque, but does not affect the installation vertical force; (ii) the ultimate uplift pressure mobilized on the helix decreases with the increase of the wing ratio; (iii) the growth rate of the helix bearing resistance with the confining pressure, for vertical stresses higher than 100 kPa, becomes reduced for piles with a larger wing ratio.
A reinterpretation of the Snow Lake gold camp, Trans-Hudson Orogen, Canada: the use of cleavages as markers to correlate structures across deformed terranes
Authors: Rubingh K.E. , Lafrance B. , Gibson H.L. 
Published: November 2020

The Snow Lake gold camp is located within amphibolite facies volcanic rocks of the ca. 1.88–1.87 Ga Flin Flon – Glennie Complex (FFGC) in the Trans-Hudson Orogen, Manitoba. During thrusting and collision with the Archean Sask craton, volcanic rocks were interleaved with turbidites of the ca. 1.855–1.84 Ga Burntwood Group and sandstone and conglomerate of the ca. 1.845–1.835 Ga Missi Group. The main cleavage in the turbidites was previously attributed to thrusting and used as a marker for correlating structures across the camp. A re-examination of this cleavage suggests that it overprints the thrust faults and formed during later collision between the FFGC and the Archean Superior craton. This has important implications as it further suggests that (1) previously unrecognized, early brittle thrust faults repeat volcanic stratigraphy and may have created the boundary conditions that enabled the formation of ductile thrust faults, fold nappes, and mega sheath folds; (2) shear sense indicators along ductile thrust faults formed during their reactivation as sinistral shear zones rather than during thrusting; and (3) peak metamorphic conditions were caused by thrusting and stacking during collision with the Sask craton but were attained later during collision with the Superior craton due to the time lag between orogenesis and the re-equilibration of regional isotherms. Results from this study may be applicable to other complexly deformed terranes where the dominant regional cleavage differs in expression in mixed volcanic and sedimentary successions and has been used as a marker for correlating structures.
PACM HCI V4 ISS, November 2020 - Editorial
Authors: Chevalier Fanny , Marquardt Nicolai 
Published: November 2020

It is our great pleasure to welcome you to this issue of the Proceedings of the ACM on Human Computer Interaction, the first to focus on the contributions from the research community Interactive Surfaces and Spaces (ISS). Interactive Surfaces and Spaces increasingly pervade our everyday life, appearing in various sizes, shapes, and application contexts, offering a rich variety of ways to interact. This diverse research community explores the design, development and use of new and emerging tabletop, digital surface, interactive spaces and multi-surface technologies.
The call for articles for this issue on ISS attracted 87 submissions, from all over the world. After the first round of reviewing, 26 (29.9%) articles with minor revisions were invited to the Revise and Resubmit phase, and 39 (44.8%) articles with major revisions for the next full PACMHCI ISS review cycle in 2021 (total of 65 articles, 74.7%). The editorial committee worked hard over the two iterations of the review process to arrive at final decisions. In the end, 25 articles (28%) were accepted. All authors of the accepted articles are invited to present at the ISS conference from November 8-11, 2020.
This issue exists because of the dedicated volunteer effort of 31 senior editors who served as Associate Chairs (ACs), and 146 expert reviewers to ensure high quality and insightful reviews for all articles in both rounds. Reviewers and committee members were kept constant for papers that submitted to both rounds.
Analysis of Chest CT Results of Coronavirus Disease 2019 (COVID-19) Patients at First Follow-Up
Authors: Zhong Lingshan , Zhang Shuo , Wang Jigang , Zhao Xinqian , Wang Kai , Ding Wenlong , Xing Zhiheng , Shen Jun 
Published: November 2020

Objective. To investigate the dissipation and outcomes of pulmonary lesions at the first follow-up of patients who recovered from moderate and severe cases of COVID-19. Methods. From January 21 to March 3, 2020, a total of 136 patients with COVID-19 were admitted to our hospital. According to inclusion and exclusion criteria, 52 patients who recovered from COVID-19 were included in this study, including 33 moderate cases and 19 severe cases. Three senior radiologists independently and retrospectively analyzed the chest CT imaging data of 52 patients at the last time of admission and the first follow-up after discharge, including primary manifestations, concomitant manifestations, and degree of residual lesion dissipation. Results. At the first follow-up after discharge, 16 patients with COVID-19 recovered to normal chest CT appearance, while 36 patients still had residual pulmonary lesions, mainly including 33 cases of ground-glass opacity, 5 cases of consolidation, and 19 cases of fibrous strip shadow. The proportion of residual pulmonary lesions in severe cases (17/19) was statistically higher than in moderate cases (19/33) (

χ

2

=

5
.
759

,

P
<
0.05

). At the first follow-up, residual pulmonary lesions were dissipated to varying degrees in 47 cases, and lesions remained unchanged in 5 cases. There were no cases of increased numbers of lesions, enlargement of lesions, or appearance of new lesions. The dissipation of residual pulmonary lesions in moderate patients was statistically better than in severe patients (Z = −2.538,

P
<
0.05

). Conclusion. Clinically cured patients with COVID-19 had faster dissipation of residual pulmonary lesions after discharge, while moderate patients had better dissipation than severe patients. However, at the first follow-up, most patients still had residual pulmonary lesions, which were primarily ground-glass opacity and fibrous strip shadow. The proportion of residual pulmonary lesions was higher in severe cases of COVID-19, which required further follow-up.
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents
Authors: Deng Manman , Xu-Monette Zijun Y. , Pham Lan V. , Wang Xudong , Tzankov Alexandar , Fang Xiaosheng , Zhu Feng , Visco Carlo , Bhagat Govind , Dybkaer Karen , Chiu April , Tam Wayne , Zu Youli , Hsi Eric D. , You Hua , Huh Jooryung , Ponzoni Maurilio , Ferreri Andrés J.M. , Møller Michael B. , Parsons Benjamin M. , Hagemeister Fredrick , van Krieken J. Han , Piris Miguel A. , Winter Jane N. , Li Yong , Xu Bing , Liu Phillip , Young Ken H. 
Published: November 2020

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the major type of aggressive B-cell lymphoma. High-grade B-cell lymphoma (HGBCL) with MYC/BCL2 double-hit (DH) represents a distinct entity with dismal prognosis after standard immunochemotherapy in the current WHO lymphoma classification. However, whether TP53 mutation synergizes with MYC abnormalities (MYC rearrangement and/or Myc protein overexpression) contributing to HGBCL-like biology and prognosis is not well investigated. In this study, patients with DLBCL with MYC/TP53 abnormalities demonstrated poor clinical outcome, high-grade morphology, and distinct gene expression signatures. To identify more effective therapies for this distinctive DLBCL subset, novel MYC/TP53/BCL-2–targeted agents were investigated in DLBCL cells with MYC/TP53 dual alterations or HGBCL-MYC/BCL2-DH. A BET inhibitor INCB057643 effectively inhibited cell viability and induced apoptosis in DLBCL/HGBCL cells regardless of MYC/BCL2/TP53 status. Combining INCB057643 with a MDM2-p53 inhibitor DS3032b significantly enhanced the cytotoxic effects in HGBCL-DH without TP53 mutation, while combining with the BCL-2 inhibitor venetoclax displayed potent therapeutic synergy in DLBCL/HGBCL cells with and without concurrent TP53 mutation. Reverse-phase protein arrays revealed the synergistic molecular actions by INCB057643, DS3032b and venetoclax to induce cell-cycle arrest and apoptosis and to inhibit AKT/MEK/ERK/mTOR pathways, as well as potential drug resistance mechanisms mediated by upregulation of Mcl-1 and RAS/RAF/MEK/ERK pathways. In summary, these findings support subclassification of DLBCL/HGBCL with dual MYC/TP53 alterations, which demonstrates distinct pathobiologic features and dismal survival with standard therapy, therefore requiring additional targeted therapies.

Implications:
The clinical and pharmacologic studies suggest recognizing DLBCL with concomitant TP53 mutation and MYC abnormalities as a distinctive entity necessary for precision oncology practice.

Visual Overview:
http://mcr.aacrjournals.org/content/molcanres/19/2/249/F1.large.jpg.
Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients With Pulmonary Arterial Hypertension
Authors: Zawia Amira , Arnold Nadine D. , West Laura , Pickworth Josephine A. , Turton Helena , Iremonger James , Braithwaite Adam T. , Cañedo Jaime , Johnston Simon A. , Thompson A.A. Roger , Miller Gaynor , Lawrie Allan 
Published: November 2020

Objective:
To determine whether global reduction of CD68 (cluster of differentiation) macrophages impacts the development of experimental pulmonary arterial hypertension (PAH) and whether this reduction affects the balance of pro- and anti-inflammatory macrophages within the lung. Additionally, to determine whether there is evidence of an altered macrophage polarization in patients with PAH.

Approach and Results:
Macrophage reduction was induced in mice via doxycycline-induced CD68-driven cytotoxic diphtheria toxin A chain expression (macrophage low [MacLow] mice). Chimeric mice were generated using bone marrow transplant. Mice were phenotyped for PAH by echocardiography and closed chest cardiac catheterization. Murine macrophage phenotyping was performed on lungs, bone marrow–derived macrophages, and alveolar macrophages using immunohistochemical and flow cytometry. Monocyte-derived macrophages were isolated from PAH patients and healthy volunteers and polarization capacity assessed morphologically and by flow cytometry. After 6 weeks of macrophage depletion, male but not female MacLow mice developed PAH. Chimeric mice demonstrated a requirement for both MacLow bone marrow and MacLow recipient mice to cause PAH. Immunohistochemical analysis of lung sections demonstrated imbalance in M1/M2 ratio in male MacLow mice only, suggesting that this imbalance may drive the PAH phenotype. M1/M2 imbalance was also seen in male MacLow bone marrow–derived macrophages and PAH patient monocyte-derived macrophages following stimulation with doxycycline and IL (interleukin)-4, respectively. Furthermore, MacLow-derived alveolar macrophages showed characteristic differences in terms of their polarization and expression of diphtheria toxin A chain following stimulation with doxycycline.

Conclusions:
These data further highlight a sex imbalance in PAH and further implicate immune cells into this paradigm. Targeting imbalance of macrophage population may offer a future therapeutic option.